For men with localized prostate cancer, radiotherapy (RT) remains a common therapeutic option. Although radiotherapy has had significant success, it remains an intractable issue in promoting radiation damage to tumor tissue while reducing adverse effects on healthy tissue. Chemicals or pharmacological substances known as radiosensitizers can increase the killing effect on tumor cells by accelerating DNA damage and indirectly producing free radicals. Of all the approaches to improving RT management outcomes, metal nanoparticle-enhanced radiation for prostate cancer patient therapy is a unique strategy that has sparked scientific attention in the past decade. Most current data is based on targeted RT with gold nanoparticles, among the most studied materials. Nevertheless, several novel materials have also been employed in preclinical settings. This study assesses existing dosimetric data on prostate cancer tissue as well as the likely future influence on treatment options and patient outcomes since further research in a clinical setting is necessary.